Neuronetics Announces Increased Transcranial Magnetic Stimulation Access Through BlueCross BlueShield Of Michigan
Portfolio Pulse from Happy Mohamed
Neuronetics announces increased access to its NeuroStar Advanced Therapy for Mental Health through a healthcare policy update from BlueCross BlueShield (BCBS) of Michigan. The policy change expands eligibility for depression patients to receive transcranial magnetic stimulation (TMS) by reducing the number of antidepressant medication attempts required.
May 26, 2023 | 1:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Neuronetics' NeuroStar TMS therapy gains increased access through a policy update from BCBS of Michigan, potentially leading to higher demand for the treatment.
The policy update from BCBS of Michigan expands eligibility for depression patients to receive Neuronetics' NeuroStar TMS therapy. This could lead to higher demand for the treatment, positively impacting Neuronetics' stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100